<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84892583393</prism:url><dc:identifier>SCOPUS_ID:84892583393</dc:identifier><eid>2-s2.0-84892583393</eid><pubmed-id>24323390</pubmed-id><prism:doi>10.1634/theoncologist.2013-0290</prism:doi><dc:title>Barriers and challenges to global clinical cancer research</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>10</citedby-count><prism:publicationName>Oncologist</prism:publicationName><source-id>12531</source-id><prism:issn>10837159 1549490X</prism:issn><prism:volume>19</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:startingPage>61</prism:startingPage><prism:endingPage>67</prism:endingPage><prism:pageRange>61-67</prism:pageRange><prism:coverDate>2014-01-22</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="24464530700"><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24464530700</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><ce:para>Background. There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. Methods. The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Webbased survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. Results. Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) atacademic hospitals (90%). Researchers from HICs weremore involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lackof time orcompeting prioritiesandprocedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. Conclusion. Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research. © AlphaMed Press 2014.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84892583393" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84892583393&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84892583393&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60103707" href="https://api.elsevier.com/content/affiliation/affiliation_id/60103707"><affilname>University of Uruguay</affilname><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60022403" href="https://api.elsevier.com/content/affiliation/affiliation_id/60022403"><affilname>Technion - Israel Institute of Technology</affilname><affiliation-city>Haifa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation id="60018144" href="https://api.elsevier.com/content/affiliation/affiliation_id/60018144"><affilname>Kobe Daigaku Igakubu Fozuku Byoin</affilname><affiliation-city>Kobe</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation id="60010294" href="https://api.elsevier.com/content/affiliation/affiliation_id/60010294"><affilname>Cairo University</affilname><affiliation-city>Cairo</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><affiliation id="60008768" href="https://api.elsevier.com/content/affiliation/affiliation_id/60008768"><affilname>Ontario Cancer Institute University of Toronto</affilname><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation id="60008088" href="https://api.elsevier.com/content/affiliation/affiliation_id/60008088"><affilname>Universidade de Sao Paulo - USP</affilname><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation id="60005512" href="https://api.elsevier.com/content/affiliation/affiliation_id/60005512"><affilname>Nizam's Institute of Medical Sciences</affilname><affiliation-city>Hyderabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation id="60002076" href="https://api.elsevier.com/content/affiliation/affiliation_id/60002076"><affilname>American Society of Clinical Oncology</affilname><affiliation-city>Alexandria</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="106423448" href="https://api.elsevier.com/content/affiliation/affiliation_id/106423448"><affilname>Latin American-Caribbean Society of Medical Oncology</affilname><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><authors><author seq="1" auid="24464530700"><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24464530700</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="2" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="3" auid="21033737100"><ce:initials>E.L.</ce:initials><ce:indexed-name>Cazap E.L.</ce:indexed-name><ce:surname>Cazap</ce:surname><ce:given-name>Eduardo L.</ce:given-name><preferred-name><ce:initials>E.L.</ce:initials><ce:indexed-name>Cazap E.</ce:indexed-name><ce:surname>Cazap</ce:surname><ce:given-name>Eduardo L.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/21033737100</author-url><affiliation id="106423448" href="https://api.elsevier.com/content/affiliation/affiliation_id/106423448"/></author><author seq="4" auid="57197179650"><ce:initials>L.B.</ce:initials><ce:indexed-name>Delgado L.B.</ce:indexed-name><ce:surname>Delgado</ce:surname><ce:given-name>Lucia Beatriz</ce:given-name><preferred-name><ce:initials>L.B.</ce:initials><ce:indexed-name>Delgado L.</ce:indexed-name><ce:surname>Delgado</ce:surname><ce:given-name>Lucia Beatriz</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57197179650</author-url><affiliation id="60103707" href="https://api.elsevier.com/content/affiliation/affiliation_id/60103707"/></author><author seq="5" auid="16233029800"><ce:initials>R.</ce:initials><ce:indexed-name>Digumarti R.</ce:indexed-name><ce:surname>Digumarti</ce:surname><ce:given-name>Raghunadharao</ce:given-name><preferred-name><ce:initials>R.</ce:initials><ce:indexed-name>Digumarti R.</ce:indexed-name><ce:surname>Digumarti</ce:surname><ce:given-name>Raghunadharao</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/16233029800</author-url><affiliation id="60005512" href="https://api.elsevier.com/content/affiliation/affiliation_id/60005512"/></author><author seq="6" auid="6602944827"><ce:initials>N.B.</ce:initials><ce:indexed-name>Leighl N.B.</ce:indexed-name><ce:surname>Leighl</ce:surname><ce:given-name>Natasha B.</ce:given-name><preferred-name><ce:initials>N.B.</ce:initials><ce:indexed-name>Leighl N.</ce:indexed-name><ce:surname>Leighl</ce:surname><ce:given-name>Natasha B.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6602944827</author-url><affiliation id="60008768" href="https://api.elsevier.com/content/affiliation/affiliation_id/60008768"/></author><author seq="7" auid="36897611800"><ce:initials>M.M.</ce:initials><ce:indexed-name>Meshref M.M.</ce:indexed-name><ce:surname>Meshref</ce:surname><ce:given-name>Mohamed M.</ce:given-name><preferred-name><ce:initials>M.M.</ce:initials><ce:indexed-name>Meshref M.</ce:indexed-name><ce:surname>Meshref</ce:surname><ce:given-name>Mohamed M.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36897611800</author-url><affiliation id="60010294" href="https://api.elsevier.com/content/affiliation/affiliation_id/60010294"/></author><author seq="8" auid="7202273337"><ce:initials>H.</ce:initials><ce:indexed-name>Minami H.</ce:indexed-name><ce:surname>Minami</ce:surname><ce:given-name>Hironobu</ce:given-name><preferred-name><ce:initials>H.</ce:initials><ce:indexed-name>Minami H.</ce:indexed-name><ce:surname>Minami</ce:surname><ce:given-name>Hironobu</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7202273337</author-url><affiliation id="60018144" href="https://api.elsevier.com/content/affiliation/affiliation_id/60018144"/></author><author seq="9" auid="23087178500"><ce:initials>E.</ce:initials><ce:indexed-name>Robinson E.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Eliezer</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Robinson E.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Eliezer</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23087178500</author-url><affiliation id="60022403" href="https://api.elsevier.com/content/affiliation/affiliation_id/60022403"/></author><author seq="10" auid="24478100100"><ce:initials>N.H.</ce:initials><ce:indexed-name>Yamaguchi N.H.</ce:indexed-name><ce:surname>Yamaguchi</ce:surname><ce:given-name>Nise Hitomi</ce:given-name><preferred-name><ce:initials>N.H.</ce:initials><ce:indexed-name>Yamaguchi N.</ce:indexed-name><ce:surname>Yamaguchi</ce:surname><ce:given-name>Nise Hitomi</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24478100100</author-url><affiliation id="60008088" href="https://api.elsevier.com/content/affiliation/affiliation_id/60008088"/></author><author seq="11" auid="47061909000"><ce:initials>D.</ce:initials><ce:indexed-name>Pyle D.</ce:indexed-name><ce:surname>Pyle</ce:surname><ce:given-name>Doug</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Pyle D.</ce:indexed-name><ce:surname>Pyle</ce:surname><ce:given-name>Doug</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/47061909000</author-url><affiliation id="60002076" href="https://api.elsevier.com/content/affiliation/affiliation_id/60002076"/></author><author seq="12" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Barrier</author-keyword><author-keyword>Cancer research</author-keyword><author-keyword>Global</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="1306" abbrev="BIOC">Cancer Research</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered year="2018" month="05" day="24" timestamp="2018-05-24T13:20:46.000046-04:00"/><ait:date-sort year="2014" month="01" day="22"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2014 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.1634/theoncologist.2013-0290</ce:doi><itemid idtype="PUI">372137214</itemid><itemid idtype="EMBASE">2014045637</itemid><itemid idtype="NURSNG">2014019408</itemid><itemid idtype="SCP">84892583393</itemid><itemid idtype="SGR">84892583393</itemid><itemid idtype="PUIsecondary">1372137214</itemid><itemid idtype="CAR-ID">629565927</itemid><itemid idtype="MEDL">24323390</itemid></itemidlist><history><date-created year="2014" month="01" day="22"/></history><dbcollection>EMBASE</dbcollection><dbcollection>NURSNG</dbcollection><dbcollection>Scopusbase</dbcollection><dbcollection>MEDL</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword>Barrier</author-keyword><author-keyword>Cancer research</author-keyword><author-keyword>Global</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">Barriers and challenges to global clinical cancer research</titletext></citation-title><author-group><author auid="24464530700" seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname><ce:given-name>Bostjan</ce:given-name></preferred-name></author><affiliation afid="60000966" country="svn"><organization>Institute of Oncology Ljubljana</organization><city-group>Ljubljana</city-group><affiliation-id afid="60000966"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name></author><affiliation afid="60031106" country="svn"><organization>University of Ljubljana</organization><city-group>Ljubljana</city-group><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="21033737100" seq="3"><ce:initials>E.L.</ce:initials><ce:indexed-name>Cazap E.L.</ce:indexed-name><ce:surname>Cazap</ce:surname><ce:given-name>Eduardo L.</ce:given-name><preferred-name><ce:initials>E.L.</ce:initials><ce:indexed-name>Cazap E.</ce:indexed-name><ce:surname>Cazap</ce:surname><ce:given-name>Eduardo L.</ce:given-name></preferred-name></author><affiliation afid="106423448" country="arg"><organization>Latin American-Caribbean Society of Medical Oncology</organization><city-group>Buenos Aires</city-group><affiliation-id afid="106423448"/><country>Argentina</country></affiliation></author-group><author-group><author auid="57197179650" seq="4"><ce:initials>L.B.</ce:initials><ce:indexed-name>Delgado L.B.</ce:indexed-name><ce:surname>Delgado</ce:surname><ce:given-name>Lucia Beatriz</ce:given-name><preferred-name><ce:initials>L.B.</ce:initials><ce:indexed-name>Delgado L.</ce:indexed-name><ce:surname>Delgado</ce:surname><ce:given-name>Lucia Beatriz</ce:given-name></preferred-name></author><affiliation afid="60103707" country="ury"><organization>Hospital de Clínicas</organization><organization>University of Uruguay</organization><city-group>Montevideo</city-group><affiliation-id afid="60103707"/><affiliation-id afid="60071610"/><country>Uruguay</country></affiliation></author-group><author-group><author auid="16233029800" seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Digumarti R.</ce:indexed-name><ce:surname>Digumarti</ce:surname><ce:given-name>Raghunadharao</ce:given-name><preferred-name><ce:initials>R.</ce:initials><ce:indexed-name>Digumarti R.</ce:indexed-name><ce:surname>Digumarti</ce:surname><ce:given-name>Raghunadharao</ce:given-name></preferred-name></author><affiliation afid="60005512" country="ind"><organization>Nizam's Institute of Medical Sciences</organization><city-group>Hyderabad</city-group><affiliation-id afid="60005512"/><country>India</country></affiliation></author-group><author-group><author auid="6602944827" seq="6"><ce:initials>N.B.</ce:initials><ce:indexed-name>Leighl N.B.</ce:indexed-name><ce:surname>Leighl</ce:surname><ce:given-name>Natasha B.</ce:given-name><preferred-name><ce:initials>N.B.</ce:initials><ce:indexed-name>Leighl N.</ce:indexed-name><ce:surname>Leighl</ce:surname><ce:given-name>Natasha B.</ce:given-name></preferred-name></author><affiliation afid="60008768" country="can"><organization>Princess Margaret Cancer Center</organization><city-group>Toronto, ON</city-group><affiliation-id afid="60008768"/><affiliation-id afid="60027817"/><country>Canada</country></affiliation></author-group><author-group><author auid="36897611800" seq="7"><ce:initials>M.M.</ce:initials><ce:indexed-name>Meshref M.M.</ce:indexed-name><ce:surname>Meshref</ce:surname><ce:given-name>Mohamed M.</ce:given-name><preferred-name><ce:initials>M.M.</ce:initials><ce:indexed-name>Meshref M.</ce:indexed-name><ce:surname>Meshref</ce:surname><ce:given-name>Mohamed M.</ce:given-name></preferred-name></author><affiliation afid="60010294" country="egy"><organization>Cairo University</organization><city-group>Cairo</city-group><affiliation-id afid="60010294"/><country>Egypt</country></affiliation></author-group><author-group><author auid="7202273337" seq="8"><ce:initials>H.</ce:initials><ce:indexed-name>Minami H.</ce:indexed-name><ce:surname>Minami</ce:surname><ce:given-name>Hironobu</ce:given-name><preferred-name><ce:initials>H.</ce:initials><ce:indexed-name>Minami H.</ce:indexed-name><ce:surname>Minami</ce:surname><ce:given-name>Hironobu</ce:given-name></preferred-name></author><affiliation afid="60018144" dptid="109722487" country="jpn"><organization>Division of Medical Oncology/Hematology</organization><organization>Kobe University Hospital</organization><city-group>Kobe</city-group><affiliation-id afid="60018144" dptid="109722487"/><country>Japan</country></affiliation></author-group><author-group><author auid="23087178500" seq="9"><ce:initials>E.</ce:initials><ce:indexed-name>Robinson E.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Eliezer</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Robinson E.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Eliezer</ce:given-name></preferred-name></author><affiliation afid="60022403" country="isr"><organization>Technion</organization><city-group>Haifa</city-group><affiliation-id afid="60022403"/><country>Israel</country></affiliation></author-group><author-group><author auid="24478100100" seq="10" date-locked="2017-12-15T20:48:34.450"><ce:initials>N.H.</ce:initials><ce:indexed-name>Yamaguchi N.H.</ce:indexed-name><ce:surname>Yamaguchi</ce:surname><ce:given-name>Nise Hitomi</ce:given-name><preferred-name><ce:initials>N.H.</ce:initials><ce:indexed-name>Yamaguchi N.</ce:indexed-name><ce:surname>Yamaguchi</ce:surname><ce:given-name>Nise Hitomi</ce:given-name></preferred-name></author><affiliation afid="60008088" dptid="114149289" country="bra"><organization>Institute of Advances in Medicine</organization><organization>University of São Paulo</organization><city-group>São Paulo</city-group><affiliation-id afid="60008088" dptid="114149289"/><country>Brazil</country></affiliation></author-group><author-group><author auid="47061909000" seq="11"><ce:initials>D.</ce:initials><ce:indexed-name>Pyle D.</ce:indexed-name><ce:surname>Pyle</ce:surname><ce:given-name>Doug</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Pyle D.</ce:indexed-name><ce:surname>Pyle</ce:surname><ce:given-name>Doug</ce:given-name></preferred-name></author><affiliation afid="60002076" country="usa"><organization>American Society of Clinical Oncology</organization><city-group>Alexandria, VA</city-group><affiliation-id afid="60002076"/><country>United States</country></affiliation></author-group><author-group><author auid="7004393140" seq="12"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><city-group>Golnik</city-group><affiliation-id afid="60078312"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname></person><affiliation country="svn"><organization>Sector of Medical Oncology</organization><organization>Institute of Oncology Ljubljana</organization><city-group>1000 Ljubljana</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><ce:para>Background. There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. Methods. The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Webbased survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. Results. Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) atacademic hospitals (90%). Researchers from HICs weremore involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lackof time orcompeting prioritiesandprocedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. Conclusion. Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research. © AlphaMed Press 2014.</ce:para></abstract></abstracts><source srcid="12531" type="j" country="usa"><sourcetitle>Oncologist</sourcetitle><sourcetitle-abbrev>Oncologist</sourcetitle-abbrev><issn type="print">10837159</issn><issn type="electronic">1549490X</issn><codencode>OCOLF</codencode><volisspag><voliss volume="19" issue="1"/><pagerange first="61" last="67"/></volisspag><publicationyear first="2014"/><publicationdate><year>2014</year><date-text xfab-added="true">2014</date-text></publicationdate><website><ce:e-address type="url">http://theoncologist.alphamedpress.org/content/19/1/61.full.pdf</ce:e-address></website></source><enhancement><classificationgroup><classifications type="ASJC"><classification>2730</classification><classification>1306</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>BIOC</classification></classifications></classificationgroup></enhancement></head><tail><bibliography refcount="27"><reference id="1"><ref-info><ref-title><ref-titletext>Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34548277030</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Berrino F.</ce:indexed-name><ce:surname>Berrino</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>De Angelis R.</ce:indexed-name><ce:surname>De Angelis</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Sant M.</ce:indexed-name><ce:surname>Sant</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lancet Oncol</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="8"/><pagerange first="773" last="783"/></ref-volisspag></ref-info><ref-fulltext>Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783.</ref-fulltext></reference><reference id="2"><ref-info><refd-itemidlist><itemid idtype="SGR">84892578663</itemid></refd-itemidlist><ref-sourcetitle>Eurocare: Protocol EUROCARE-5.</ref-sourcetitle><ref-website><ce:e-address type="url">http://www.eurocare.it/Eurocare5/DocumentsEU5/tabid/91/Default.aspx</ce:e-address></ref-website><ref-text>Available at, Accessed March 23, 2013</ref-text></ref-info><ref-fulltext>Eurocare: Protocol EUROCARE-5. Available at http://www. eurocare. it/Eurocare5/DocumentsEU5/ tabid/91/Default. aspx. Accessed March 23, 2013.</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Pattern of careand impact of participation in clinical studieson the outcome in ovarian cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">14044268304</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>DuBois A.</ce:indexed-name><ce:surname>DuBois</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Rochon J.</ce:indexed-name><ce:surname>Rochon</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Lamparter C.</ce:indexed-name><ce:surname>Lamparter</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Int J Gynecol Cancer</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="15"/><pagerange first="183" last="191"/></ref-volisspag></ref-info><ref-fulltext>DuBois A, Rochon J, Lamparter C et al. Pattern of careand impact of participation in clinical studieson the outcome in ovarian cancer. Int J Gynecol Cancer 2005; 15: 183-191.</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Outcomesof patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">55049135606</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.E.</ce:initials><ce:indexed-name>Vist G.E.</ce:indexed-name><ce:surname>Vist</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Bryant D.</ce:indexed-name><ce:surname>Bryant</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Somerville L.</ce:indexed-name><ce:surname>Somerville</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cochrane Database Syst Rev</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><pages>MR000009</pages></ref-volisspag></ref-info><ref-fulltext>Vist GE, Bryant D, Somerville L et al. Outcomesof patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008; MR000009.</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Improving cancer outcomes through international collaboration in academic cancer treatment trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77649159312</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.L.</ce:initials><ce:indexed-name>Trimble E.L.</ce:indexed-name><ce:surname>Trimble</ce:surname></author><author seq="2"><ce:initials>J.S.</ce:initials><ce:indexed-name>Abrams J.S.</ce:indexed-name><ce:surname>Abrams</ce:surname></author><author seq="3"><ce:initials>R.M.</ce:initials><ce:indexed-name>Meyer R.M.</ce:indexed-name><ce:surname>Meyer</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="27"/><pagerange first="5109" last="5114"/></ref-volisspag></ref-info><ref-fulltext>Trimble EL, Abrams JS, Meyer RM et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol 2009; 27: 5109-5114.</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Clinical cancer research in Latin America</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84892597829</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Delgado L.</ce:indexed-name><ce:surname>Delgado</ce:surname></author></ref-authors><ref-sourcetitle>ASCO Daily News</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><pages>3C</pages></ref-volisspag><ref-text>June 7</ref-text></ref-info><ref-fulltext>Delgado L. Clinical cancer research in Latin America. ASCO Daily News. June 7, 2010: 3C.</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Global core competencies for clinical trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84865371551</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Steinhausen K.</ce:indexed-name><ce:surname>Steinhausen</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Ren J.</ce:indexed-name><ce:surname>Ren</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Cazap E.</ce:indexed-name><ce:surname>Cazap</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="380"/><pagerange first="728"/></ref-volisspag></ref-info><ref-fulltext>Steinhausen K, Ren J, Cazap E et al. Global core competencies for clinical trials. Lancet 2012; 380: 728.</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Global drug development in cancer: A cross-sectional study of clinical trial registries</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77951964372</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Seruga B.</ce:indexed-name><ce:surname>Seruga</ce:surname></author><author seq="2"><ce:initials>P.C.</ce:initials><ce:indexed-name>Hertz P.C.</ce:indexed-name><ce:surname>Hertz</ce:surname></author><author seq="3"><ce:initials>L.W.</ce:initials><ce:indexed-name>Le L.W.</ce:indexed-name><ce:surname>Le</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="21"/><pagerange first="895" last="900"/></ref-volisspag></ref-info><ref-fulltext>Seruga B, Hertz PC, Le LW et al. Global drug development in cancer: A cross-sectional study of clinical trial registries. Ann Oncol 2010; 21: 895-900.</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035869003</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.N.</ce:initials><ce:indexed-name>Lara Jr. P.N.</ce:indexed-name><ce:surname>Lara Jr.</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Higdon R.</ce:indexed-name><ce:surname>Higdon</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Lim N.</ce:indexed-name><ce:surname>Lim</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="19"/><pagerange first="1728" last="1733"/></ref-volisspag></ref-info><ref-fulltext>Lara PN Jr., Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.</ref-fulltext></reference><reference id="10"><ref-info><refd-itemidlist><itemid idtype="SGR">84892602180</itemid></refd-itemidlist><ref-sourcetitle>3 Year Progress Report 2001-2004.</ref-sourcetitle><ref-publicationyear first="2004"/><ref-text>London, U.K.: National Cancer Research Institute</ref-text></ref-info><ref-fulltext>3 Year Progress Report 2001-2004. London, U. K.: National Cancer Research Institute, 2004.</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>The U. S. pediatric cancer clinical trials programmes: International implications and the way forward</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0030870109</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.A.</ce:initials><ce:indexed-name>Bleyer W.A.</ce:indexed-name><ce:surname>Bleyer</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="1997"/><ref-volisspag><voliss volume="33"/><pagerange first="1439" last="1447"/></ref-volisspag></ref-info><ref-fulltext>Bleyer WA. The U. S. pediatric cancer clinical trials programmes: International implications and the way forward. Eur J Cancer 1997; 33: 1439-1447.</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Organizational barriers to physician participation in cancer clinical trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">22544460783</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.P.</ce:initials><ce:indexed-name>Somkin C.P.</ce:indexed-name><ce:surname>Somkin</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Altschuler A.</ce:indexed-name><ce:surname>Altschuler</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Ackerson L.</ce:indexed-name><ce:surname>Ackerson</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Am J Manag Care</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="11"/><pagerange first="413" last="421"/></ref-volisspag></ref-info><ref-fulltext>Somkin CP, Altschuler A, Ackerson L et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care 2005; 11: 413-421.</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Evolution of the randomized controlled trial in oncology over three decades</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">56749154421</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.M.</ce:initials><ce:indexed-name>Booth C.M.</ce:indexed-name><ce:surname>Booth</ce:surname></author><author seq="2"><ce:initials>D.W.</ce:initials><ce:indexed-name>Cescon D.W.</ce:indexed-name><ce:surname>Cescon</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Wang L.</ce:indexed-name><ce:surname>Wang</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="26"/><pagerange first="5458" last="5464"/></ref-volisspag></ref-info><ref-fulltext>Booth CM, Cescon DW, Wang L et al. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008; 26: 5458-5464.</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Why don't cancer patients enter clinical trials? A review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33746636478</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Castel P.</ce:indexed-name><ce:surname>Castel</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Negrier S.</ce:indexed-name><ce:surname>Négrier</ce:surname></author><author seq="3"><ce:initials>J.P.</ce:initials><ce:indexed-name>Boissel J.P.</ce:indexed-name><ce:surname>Boissel</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="42"/><pagerange first="1744" last="1748"/></ref-volisspag><ref-text>Plateforme d'Aideà la Recherche Clinique en Cancérologie de la région Rhône-Alpes</ref-text></ref-info><ref-fulltext>Castel P, Négrier S, Boissel JP; Plateforme d'Aideà la Recherche Clinique en Cancérologie de la région Rhône-Alpes. Why don't cancer patients enter clinical trials? A review. Eur J Cancer 2006; 42: 1744-1748.</ref-fulltext></reference><reference id="15"><ref-info><refd-itemidlist><itemid idtype="SGR">79959795253</itemid></refd-itemidlist><ref-sourcetitle>How we classify countries</ref-sourcetitle><ref-website><ce:e-address type="url">http://data.worldbank.org/about/countryclassifications</ce:e-address></ref-website><ref-text>World Bank., Available at, Accessed October 2011</ref-text></ref-info><ref-fulltext>World Bank. How we classify countries. Available at http://data. worldbank. org/about/countryclassifications. Accessed October 2011.</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>How sociodemographics, presence ofoncology specialists, and hospital cancer programs affect accrual to cancer treatment trials</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0037089630</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.B.</ce:initials><ce:indexed-name>Sateren W.B.</ce:indexed-name><ce:surname>Sateren</ce:surname></author><author seq="2"><ce:initials>E.L.</ce:initials><ce:indexed-name>Trimble E.L.</ce:indexed-name><ce:surname>Trimble</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Abrams J.</ce:indexed-name><ce:surname>Abrams</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="20"/><pagerange first="2109" last="2117"/></ref-volisspag></ref-info><ref-fulltext>Sateren WB, Trimble EL, Abrams J et al. How sociodemographics, presence ofoncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002; 20: 2109-2117.</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Achieving high cancer control trial enrollment in the community setting: An analysis of the Community Clinical Oncology Program</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84873157529</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.R.</ce:initials><ce:indexed-name>Jacobs S.R.</ce:indexed-name><ce:surname>Jacobs</ce:surname></author><author seq="2"><ce:initials>B.J.</ce:initials><ce:indexed-name>Weiner B.J.</ce:indexed-name><ce:surname>Weiner</ce:surname></author><author seq="3"><ce:initials>L.M.</ce:initials><ce:indexed-name>Minasian L.M.</ce:indexed-name><ce:surname>Minasian</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Contemp Clin Trials</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="34"/><pagerange first="320" last="325"/></ref-volisspag></ref-info><ref-fulltext>Jacobs SR, Weiner BJ, Minasian LM et al. Achieving high cancer control trial enrollment in the community setting: An analysis of the Community Clinical Oncology Program. Contemp Clin Trials 2013; 34: 320-325.</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84872721339</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.F.</ce:initials><ce:indexed-name>Kanarek N.F.</ce:indexed-name><ce:surname>Kanarek</ce:surname></author><author seq="2"><ce:initials>M.S.</ce:initials><ce:indexed-name>Kanarek M.S.</ce:indexed-name><ce:surname>Kanarek</ce:surname></author><author seq="3"><ce:initials>D.</ce:initials><ce:indexed-name>Olatoye D.</ce:indexed-name><ce:surname>Olatoye</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Trials</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="13"/><pagerange first="237"/></ref-volisspag></ref-info><ref-fulltext>Kanarek NF, Kanarek MS, Olatoye D et al. Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials 2012; 13: 237.</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>Physician characteristics associated with clinical trial enrollment</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80051593555</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.K.</ce:initials><ce:indexed-name>Barton M.K.</ce:indexed-name><ce:surname>Barton</ce:surname></author></ref-authors><ref-sourcetitle>CA Cancer J Clin</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="61"/><pagerange first="207" last="208"/></ref-volisspag></ref-info><ref-fulltext>Barton MK. Physician characteristics associated with clinical trial enrollment. CA Cancer J Clin 2011; 61: 207-208.</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>The impact of the 'Clinical Trials' directive on the cost and conduct of noncommercial cancer trials in the UK</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33846020021</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Hearn J.</ce:indexed-name><ce:surname>Hearn</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Sullivan R.</ce:indexed-name><ce:surname>Sullivan</ce:surname></author></ref-authors><ref-sourcetitle>Eur J Cancer</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="43"/><pagerange first="8" last="13"/></ref-volisspag></ref-info><ref-fulltext>Hearn J, Sullivan R. The impact of the 'Clinical Trials' directive on the cost and conduct of noncommercial cancer trials in the UK. Eur J Cancer 2007; 43: 8-13.</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Ethical and scientific implications of the globalization of clinical research</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">60849106348</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.W.</ce:initials><ce:indexed-name>Glickman S.W.</ce:indexed-name><ce:surname>Glickman</ce:surname></author><author seq="2"><ce:initials>J.G.</ce:initials><ce:indexed-name>McHutchison J.G.</ce:indexed-name><ce:surname>McHutchison</ce:surname></author><author seq="3"><ce:initials>E.D.</ce:initials><ce:indexed-name>Peterson E.D.</ce:indexed-name><ce:surname>Peterson</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>N Engl J Med</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="360"/><pagerange first="816" last="823"/></ref-volisspag></ref-info><ref-fulltext>Glickman SW, McHutchison JG, Peterson ED et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009; 360: 816-823.</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>The good, the bad, and the ugly: Effect of regulations on cancer research</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">37449032173</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Sullivan R.</ce:indexed-name><ce:surname>Sullivan</ce:surname></author></ref-authors><ref-sourcetitle>Lancet Oncol</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="9"/><pagerange first="2" last="3"/></ref-volisspag></ref-info><ref-fulltext>Sullivan R. The good, the bad, and the ugly: Effect of regulations on cancer research. Lancet Oncol 2008; 9: 2-3.</ref-fulltext></reference><reference id="23"><ref-info><refd-itemidlist><itemid idtype="SGR">84892571462</itemid></refd-itemidlist><ref-sourcetitle>Conference on the Impact on Clinical Research of European Legislation-ICREL: Results &amp; discussion.</ref-sourcetitle><ref-website><ce:e-address type="url">http://pt.wkhealth.com/pt/pt-core/template-adis/jpm/media/ICREL.pdf</ce:e-address></ref-website><ref-text>Available at, Accessed April 7, 2013</ref-text></ref-info><ref-fulltext>Conference on the Impact on Clinical Research of European Legislation-ICREL: Results &amp; discussion. Available athttp://pt. wkhealth. com/pt/pt-core/ template-adis/jpm/media/ICREL. pdf. Accessed April 7, 2013.</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Keeping faith with trial volunteers</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33947099048</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Piccart M.</ce:indexed-name><ce:surname>Piccart</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Goldhirsch A.</ce:indexed-name><ce:surname>Goldhirsch</ce:surname></author><author seq="3"><ce:initials>W.</ce:initials><ce:indexed-name>Wood W.</ce:indexed-name><ce:surname>Wood</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Nature</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="446"/><pagerange first="137" last="138"/></ref-volisspag></ref-info><ref-fulltext>Piccart M, Goldhirsch A, Wood W et al. Keeping faith with trial volunteers. Nature 2007; 446: 137-138.</ref-fulltext></reference><reference id="25"><ref-info><ref-title><ref-titletext>Clinical trial registration: A statement from the International Committee of Medical Journal Editors</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">4544295352</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>De Angelis C.</ce:indexed-name><ce:surname>De Angelis</ce:surname></author><author seq="2"><ce:initials>J.M.</ce:initials><ce:indexed-name>Drazen J.M.</ce:indexed-name><ce:surname>Drazen</ce:surname></author><author seq="3"><ce:initials>F.A.</ce:initials><ce:indexed-name>Frizelle F.A.</ce:indexed-name><ce:surname>Frizelle</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>N Engl J Med</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="351"/><pagerange first="1250" last="1251"/></ref-volisspag></ref-info><ref-fulltext>De Angelis C, Drazen JM, Frizelle FA et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351: 1250-1251.</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>The transition fromphase II to phase III studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">61449143514</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.R.</ce:initials><ce:indexed-name>Berthold D.R.</ce:indexed-name><ce:surname>Berthold</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Gulamhusein A.</ce:indexed-name><ce:surname>Gulamhusein</ce:surname></author><author seq="3"><ce:initials>J.I.</ce:initials><ce:indexed-name>Jackson J.I.</ce:indexed-name><ce:surname>Jackson</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="27"/><pagerange first="1150" last="1151"/></ref-volisspag></ref-info><ref-fulltext>Berthold DR, Gulamhusein A, Jackson JI et al. The transition fromphase II to phase III studies. J Clin Oncol 2009; 27: 1150-1151.</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>A survey of public funding of cancer research in the European Union</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33746391933</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Eckhouse S.</ce:indexed-name><ce:surname>Eckhouse</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Sullivan R.</ce:indexed-name><ce:surname>Sullivan</ce:surname></author></ref-authors><ref-sourcetitle>PLoS Med</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="3"/><pages>e267</pages></ref-volisspag></ref-info><ref-fulltext>Eckhouse S, Sullivan R. A survey of public funding of cancer research in the European Union. PLoS Med 2006; 3: e267.</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>